Patents by Inventor Thanh Barbie

Thanh Barbie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STING LEVELS AS A BIOMARKER FOR CANCER IMMUNOTHERAPY
    Publication number: 20240125787
    Abstract: Provided herein are STING and SPARCS genes as biomarkers for determining an effective therapy for treating cancer. Further provided are methods for treating cancer using said biomarkers.
    Type: Application
    Filed: December 5, 2023
    Publication date: April 18, 2024
    Applicants: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: David Barbie, Israel Cañadas, Shunsuke Kitajima, Thanh Barbie
  • STING levels as a biomarker for cancer immunotherapy
    Patent number: 11874276
    Abstract: Provided herein are Stimulator of Interferon Genes (STING) and Stimulated 3 Prime Antisense Retroviral Coding Sequences (SPARCS) genes as biomarkers for determining an effective therapy for treating cancer. Further provided are methods for treating cancer using said biomarkers.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: January 16, 2024
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: David Barbie, Israel Cañadas, Shunsuke Kitajima, Thanh Barbie
  • STING LEVELS AS A BIOMARKER FOR CANCER IMMUNOTHERAPY
    Publication number: 20210025893
    Abstract: Provided herein are STING and SPARCS genes as biomarkers for determining an effective therapy for treating cancer. Further provided are methods for treating cancer using said biomarkers.
    Type: Application
    Filed: April 5, 2019
    Publication date: January 28, 2021
    Applicants: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital Inc.
    Inventors: David Barbie, Israel Cañadas, Shunsuke Kitajima, Thanh Barbie
  • MICROFLUIDIC CELL CULTURE OF PATIENT-DERIVED TUMOR CELL SPHEROIDS
    Publication number: 20200399573
    Abstract: Provided herein are methods for culturing patient-derived tumor cell spheroids in a three-dimensional microfluidic device. The method comprises mincing primary tumor sample in a medium supplemented with serum; treating the minced primary tumor sample with a composition comprising an enzyme; collecting tumor spheroids having a diameter of 10 ?m to 500 ?m from the enzyme treated sample; suspending the tumor spheroids in biocompatible gel; and culturing the tumor spheroids in a three dimensional microfluidic device. Methods for identifying an agent for treating cancer and microfluidic devices that allow for the simultaneous exposure of the cultured patient-derived primary tumor cell spheroids to a treatment of choice and to control treatment are also provided.
    Type: Application
    Filed: October 2, 2019
    Publication date: December 24, 2020
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: David Barbie, Amir Aref, Thanh Barbie, Russell W. Jenkins, Kwok-kin Wong
  • MICROFLUIDIC CELL CULTURE OF PATIENT-DERIVED TUMOR CELL SPHEROIDS
    Publication number: 20200032187
    Abstract: Provided herein are methods for culturing patient-derived tumor cell spheroids in a three-dimensional microfluidic device. The method comprises mincing primary tumor sample in a medium supplemented with serum; treating the minced primary tumor sample with a composition comprising an enzyme; collecting tumor spheroids having a diameter of 10 ?m to 500 ?m from the enzyme treated sample; suspending the tumor spheroids in biocompatible gel; and culturing the tumor spheroids in a three dimensional microfluidic device. Methods for identifying an agent for treating cancer and microfluidic devices that allow for the simultaneous exposure of the cultured patient-derived primary tumor cell spheroids to a treatment of choice and to control treatment are also provided.
    Type: Application
    Filed: October 2, 2019
    Publication date: January 30, 2020
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: David Barbie, Amir Aref, Thanh Barbie, Russell W. Jenkins, Kwok-kin Wong
  • Microfluidic cell culture of patient-derived tumor cell spheroids
    Patent number: 10472599
    Abstract: Provided herein are methods for culturing patient-derived tumor cell spheroids in a three-dimensional microfluidic device. The method comprises mincing primary tumor sample in a medium supplemented with serum; treating the minced primary tumor sample with a composition comprising an enzyme; collecting tumor spheroids having a diameter of 10 ?m to 500 ?m from the enzyme treated sample; suspending the tumor spheroids in biocompatible gel; and culturing the tumor spheroids in a three dimensional microfluidic device. Methods for identifying an agent for treating cancer and microfluidic devices that allow for the simultaneous exposure of the cultured patient-derived primary tumor cell spheroids to a treatment of choice and to control treatment are also provided.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: November 12, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: David Barbie, Amir Aref, Thanh Barbie, Russell W. Jenkins, Kwok-kin Wong
  • MICROFLUIDIC CELL CULTURE OF PATIENT-DERIVED TUMOR CELL SPHEROIDS
    Publication number: 20170369829
    Abstract: Provided herein are methods for culturing patient-derived tumor cell spheroids in a three-dimensional microfluidic device. The method comprises mincing primary tumor sample in a medium supplemented with serum; treating the minced primary tumor sample with a composition comprising an enzyme; collecting tumor spheroids having a diameter of 10 ?m to 500 ?m from the enzyme treated sample; suspending the tumor spheroids in biocompatible gel; and culturing the tumor spheroids in a three dimensional microfluidic device. Methods for identifying an agent for treating cancer and microfluidic devices that allow for the simultaneous exposure of the cultured patient-derived primary tumor cell spheroids to a treatment of choice and to control treatment are also provided.
    Type: Application
    Filed: January 7, 2016
    Publication date: December 28, 2017
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: David Barbie, Amir Aref, Thanh Barbie, Russell W. Jenkins, Kwok-kin Wong